Video

Dr. Alexis Rompré-Brodeur on germline testing in renal cell carcinoma

Author(s):

Urology Times staff
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Alexis Rompré-Brodeur, MD, a urologic oncologist at McGill University discusses germline testing in patients with renal cell carcinoma. Rompré-Brodeur presented the study, “Germline testing in renal cell carcinoma: can enrichment features help predict germline alterations?” at the 2022 AUA Annual Meeting.

      Related Videos
      Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
      Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
      Paul Sieber, MD, on the future of genetic testing in prostate cancer
      Paul Sieber, MD, on the future of genetic testing in prostate cancer
      Daniel Kwon, MD, answers a question during a Zoom video interview
      Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer
      Tim Richardson, MD, on genetic testing in the era of targeted therapies
      Tim Richardson, MD, on genetic testing in the era of targeted therapies
      DNA helix | Image Credit: © BillionPhotos.com - stock.adobe.com
      Discussing germline testing for prostate cancer with veterans
      Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing
      Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing
      Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer
      Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer
      DNA molecules | Image Credit: © vitstudio - stock.adobe.com
      Germline testing study’s implications for veteran access to prostate cancer treatments
      Kara Cossis, PA-C, MPH, on challenges, opportunities with genetic testing
      Kara Cossis, PA-C, MPH, on challenges, opportunities with genetic testing
      Daniel Kwon, MD, answers a question during a Zoom video interview
      Daniel Kwon, MD, on germline testing for prostate cancer in veterans with service-connected benefits
      Related Content
      Study shows value of precision-based approaches in prostate cancer
      May 19th 2025

      Study shows value of precision-based approaches in prostate cancer

      Hannah Clarke
      The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.
      Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer
      February 25th 2025

      Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

      Hannah Clarke
      Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.
      Pathogenic variants of WNT9B gene linked to hereditary prostate cancer
      January 29th 2025

      Pathogenic variants of WNT9B gene linked to hereditary prostate cancer

      Hannah Clarke
      WNT9B E152K was associated with a 2.5-fold increase in the risk of prostate cancer and reached genome-wide significance.
      Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear
      January 22nd 2025

      Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear

      Hannah Clarke
      "[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.
      3d rendered genetic illustration of human dna under microscope created with generative ai technology | Image Credit: © Picture Studio - stock.adobe.com
      December 24th 2024

      Quiz: CUA guidelines on specimen and timing considerations with genetic testing

      Patrick Campbell
      Test your knowledge of these often-overlooked but essential aspects of genetic and genomic testing.
      NCCN reaffirms Prolaris’ prognostic value in prostate cancer
      December 18th 2024

      NCCN reaffirms Prolaris’ prognostic value in prostate cancer

      Hannah Clarke
      The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.
      © 2025 MJH Life Sciences

      All rights reserved.